抗肿瘤药物相关间质性肺疾病发病机制研究进展  

Research Progress of Pathogenesis of Antineoplastic Drug Associated Interstitial Lung Disease

作　　者：詹峰 王迎难 聂婷婷 伍旭 来宇航 倪吉祥 ZHAN Feng;WANG Yingnan;NIE Tingting;WU Xu;LAI Yuhang;NI Jixiang(The First College of Clinical Medical Science,China Three Gorges University,Yichang 443003,China;Department of Respiratory and Critical Care Medicine,Yichang Central People's Hospital,Yichang 443003,China;Department of Respiratory and Critical Care Medicine,the Central Hospital of Wuhan,Wuhan 430014,China)

机构地区：[1]三峡大学第一临床医学院,湖北宜昌443003 [2]宜昌市中心人民医院呼吸与危重症医学科,湖北宜昌443003 [3]武汉市中心医院呼吸与危重症医学科,武汉430014

出　　处：《医学综述》2025年第7期813-819,共7页Medical Recapitulate

基　　金：宜昌市医疗卫生研究项目(A24-2-023)。

摘　　要：间质性肺疾病(ILD)是抗肿瘤药物在临床应用中常见的肺部不良反应之一。其发病机制目前尚未完全明确,抗肿瘤药物诱导的肺损伤可能通过免疫反应、氧化应激、炎症反应及细胞凋亡等途径引发ILD。抗肿瘤药物的不同机制对肺组织的损伤具有不同的特征,其临床表现及病理类型多样且缺乏特异性诊断标准。尽管治疗方法逐渐多样化,但目前针对抗肿瘤药物相关ILD的预防和治疗仍存在较大挑战。未来应进一步探索抗肿瘤药物相关ILD的确切发病机制,从而为减少其发生及改善患者预后提供帮助。Interstitial lung disease(ILD)is a common pulmonary adverse reaction associated with the clinical application of antineoplastic drug.The underlying pathogenesis remains incompletely understood,but antineoplastic drug-induced lung injury may trigger ILD through mechanisms involving immune responses,oxidative stress,inflammatory pathways,and apoptosis.The different mechanisms of antineoplastic drugs have different characteristics of damage to lung tissue,with diverse clinical manifestations and pathological types lacking specific diagnostic criteria.Although the therapeutic options are expanding,significant challenges persist in the prevention and treatment of antineoplastic drug associated ILD.In the future,further exploration should be conducted on the exact pathogenesis of ILD related to antineoplastic drugs,in order to provide assistance in reducing its occurrence and improving the patient prognosis.

关 键 词：间质性肺疾病 抗肿瘤药物 肺损伤 

分 类 号：R563[医药卫生—呼吸系统]